Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
Published on
⇢ Registration is now open for those wishing to attend either in person in Villejuif or online.
Gustave Roussy and The Lancet have partnered to create the Lecture Series on Cancer Breakthroughs, a new programme of lectures dedicated to major advances in the fight against cancer. This annual event aims to bring together leading research, innovation and public health perspectives around the developments that are reshaping oncology.
The inaugural lecture of this partnership will take place on Friday 18 September at 5:00 pm in Villejuif. It will be delivered by Professor Timothy R. Rebbeck, an internationally renowned epidemiologist and specialist in personalised cancer prevention. Holder of the Vincent L. Gregory Chair in Cancer Prevention at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute, Professor Rebbeck’s work is helping to redefine prevention strategies in the era of precision medicine and has led to major advances in several fields, including:
-
Improving our understanding of cancer risks associated with BRCA gene mutations.
-
Demonstrating the effectiveness of preventive surgery for patients with a high genetic risk of cancer.
-
Investigating inequalities in prostate cancer risk and outcomes..
Programme
-
5:00 pm. Introduction
-
Vania Wisdom, The Lancet, United Kingdom.
-
-
5:10. Lecture by Professor Timothy R. Rebbeck - Harvard T.H. Chan School of Public Health & Dana-Farber Cancer Institute, United States.
-
5:55 pm. Panel discussion
-
Professor Timothy R. Rebbeck, Harvard T.H. Chan School of Public Health & Dana-Farber Cancer Institute, United States.
-
Dr Judith Balmaña, Vall d’Hebron Institute of Oncology, Spain.
-
Dr Suzette Delaloge, Institut national du cancer and Gustave Roussy, France.
-
-
6:40 pm. Q&A
-
7:00 pm. Closing remarks
-
Vania Wisdom, The Lancet, United Kingdom.
-
Professor Fabrice Barlesi, Gustave Roussy, France.
-
A lecture exploring different aspects of cancer prevention
Professor Rebbeck’s lecture on 18 September will explore how advances in precision medicine are transforming the way cancer is approached.
For many years, efforts to combat cancer focused primarily on diagnosis and treatment once the disease developed. Today, by analysing genetic data, lifestyle factors, and environmental exposures, scientists can increasingly identify individuals at highest risk of developing certain cancers and intervene earlier, sometimes even before the first signs of disease appear.
The lecture will be followed by a panel discussion featuring, among others, Dr Judith Balmaña from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. An expert in inherited cancer predisposition, particularly breast and ovarian cancers associated with the BRCA1 and BRCA2 genes, her research focuses on the interpretation of genetic variants, PARP inhibitors, and Lynch syndrome. She has also contributed to several European clinical practice guidelines in the field of cancer genetics.
Practical Information
-
Lecture Series on Cancer Breakthroughs: Personalized Cancer Prevention.
-
Friday 18 September, 5:00 pm.
-
Online and in person at 125 Rue Édouard Vaillant, 94800 Villejuif, France.
-
Attendance is free of charge, but registration is required via the dedicated platform.
Last news
-
Nuclear medicine: DART, a pioneering platform for the development of alpha therapy
Developed through a partnership between Gustave Roussy and the Paris-Saclay Cancer Cluster, the DART project aims to provide industry partners with a centre of excellence spanning preclinical, clinical and translational research to support the development of alpha therapy. This innovative nuclear medicine approach can destroy cancer cells more powerfully than standard approaches while reducing damage to surrounding healthy cells.
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
